Ulcerative Colitis

Findings from cross-sectional and predictive analyses of patients with UC treated with upadacitinib revealed HEMR and HEMI are associated with positive long-term clinical outcomes.

AbbVie submitted regulatory applications to the FDA and EMA for rizankizumab 1200 mg intravenous induction dose and 180 mg and 360 mg subcutaneous maintenance dose following successful Phase 3 trials INSPIRE and COMMAND.

There were higher percentages of patients treated with mirikizumab that had clinical remission at week 12 of the induction trial compared to the placebo group. This was also true at week 40 of the maintenance trial.

In recent years trial designs have evolved to become increasingly complex and sophisticated with new endpoints that could include patient-reported outcomes, biomarkers, mucosal, and histological healing, central endoscopy reading, and trials that examine both induction and maintenance of remission within the same study.

There were no new safety signals identified from the COMMAND trial.

In the maintenance period, 86% of patients treated icanbelimod completed and 67% achieved clinical remission through week 48.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.

Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.

Dr David Hudesman, Dr Jordan Axelrad, and Dr Jose Scher discuss strategies for managing coexisting inflammatory bowel disease and psoriatic arthritis and highlight the importance of a multidisciplinary approach to providing comprehensive care.

No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.

Small molecule therapies offer patients with mild or moderate inflammatory bowel disease a much cheaper alternative to biologics.

A diet that is high in sugar, fried foods, and lacks vegetables increases the risk of pediatric inflammatory bowel disease.

Expert gastroenterologists delve into the long-term management of Crohn’s disease and ulcerative colitis and examine the latest treatment options and strategies to enhance patient outcomes.

There remains a need for more biosimilars in gastroenterology.

Patients in long-remission also presented with fecal bacterial composition that was similar to what was found in the healthy control group and there was a positive correlation between Akkermansia muciniphila abundance and time in remission.

Disease activity and treatment with a small-molecule or an investigation drug were independently linked to an exclusion diet, while a history of stenosis and active disease were associated with fasting.

The results show 52.5% of patients achieved clinical remission at week 96, while 59.0% saw endoscopic improvement, 35.9% achieved endoscopic remission, and 70.5% achieved a clinical response.

There are many reasons why biosimilars are not utilized in gastroenterology, mainly patients present younger and treatments can lose efficacy over time.

Some traditional sarcopenia assessment techniques included direct measurements on cross sectional imaging, but cross sectional imaging also comes with increased time, cost, and radiation exposure.

Using the bidirectional Montreal classification system, which accounts for disease regression, showed that 90% of patients exhibited inflammatory disease behavior at 5 years, compared to 58% if the hierarchical, unidirectional Montreal classification system was implemented.

The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.

Patients at a risk of malnutrition had a significantly lower mean of albumin, as well as significantly increased proportion of patients with CRP >5 mg/L.